For decades, the dialogue between the FDA and drug sponsors was the industry’s best-kept secret. If an application didn't cross the finish line, the "why" was often buried in a Complete Response Letter (CRL) that only the sponsor ever saw. That era is officially over. Under the leadership of Commissioner Dr. Marty Makary, the FDA [...]